Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
Taru A MuranenDario GrecoCarl BlomqvistKristiina AittomäkiSofia KhanFrans HogervorstSenno VerhoefPaul D P PharoahAlison M DunningMitul ShahRobert LubenStig E BojesenBørge G NordestgaardMinouk SchoemakerAnthony J SwerdlowMontserrat García-ClosasJonine FigueroaThilo DörkNatalia V BogdanovaPer HallJingmei LiElza KhusnutdinovaMarina BermishevaVessela KristensenAnne-Lise Borresen-Dalenull nullJulian PetoIsabel Dos Santos SilvaFergus J CouchJanet E OlsonPeter HillemannsTjoung-Won Park-SimonHiltrud BrauchUte HamannBarbara BurwinkelFrederik MarmeAlfons MeindlRita K SchmutzlerAngela CoxSimon S CrossElinor J SawyerIan TomlinsonDiether LambrechtsMatthieu MoisseAnnika LindblomSara MargolinAntoinette HollestelleJohn W M MartensPeter A FaschingMatthias W BeckmannIrene L AndrulisJulia A Knightnull nullHoda Anton-CulverArgyrios ZiogasGraham G GilesRoger L MilneHermann BrennerVolker ArndtArto MannermaaVeli-Matti KosmaJenny Chang-ClaudeAnja RudolphPeter DevileeCaroline SeynaeveJohn L HopperMelissa C SoutheyEsther M JohnAlice S WhittemoreManjeet K BollaQin WangKyriaki MichailidouJoe G DennisDouglas F EastonMarjanka K SchmidtHeli NevanlinnaPublished in: Genetics in medicine : official journal of the American College of Medical Genetics (2016)
Our results confirm the multiplicative nature of risk effects conferred by CHEK2*1100delC and the common susceptibility variants. Furthermore, the PRS could identify carriers at a high lifetime risk for clinical actions.Genet Med advance online publication 06 October 2016.